Scientific advances are uncovering ever greater opportunities for therapeutic development, yet resources in the traditional biopharma business models are stretched thin, and even the most scientifically validated approach might fall by the wayside due to conflicts with pharma company focus areas, lower potential revenues upon commercialization or the scientific challenge. To meet this need, a crop of new companies is emerging, daring to build businesses that are based on dramatically different financing models in order to push the scientific envelope.
In this panel, leaders of nontraditional biotechs will discuss the market conditions that necessitated a different funding approach, how their specific approaches can potentially bring therapies to patients that otherwise might not see the light of day and give advice on how other companies might follow in their footsteps to buck the traditional biotech company formation approach.

Ability Level: All

Session ID: 21163